Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ethotoin
Drug ID BADD_D00847
Description Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used.
Indications and Usage For the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures.
Marketing Status approved
ATC Code N03AB01
DrugBank ID DB00754
KEGG ID D00708
MeSH ID C084606
PubChem ID 3292
TTD Drug ID D05EPM
NDC Product Code 45562-1133
UNII 46QG38NC4U
Synonyms ethotoin | Peganone
Chemical Information
Molecular Formula C11H12N2O2
CAS Registry Number 86-35-1
SMILES CCN1C(=O)C(NC1=O)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Body temperature increased13.15.01.001--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dyspepsia07.01.02.001--
Erythema multiforme23.03.01.003; 10.01.03.015--
Fatigue08.01.01.002--
Gingival hypertrophy07.09.13.008--Not Available
Headache17.14.01.001--
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Lymphadenopathy01.09.01.002--Not Available
Lymphoma01.12.01.001; 16.20.01.001--Not Available
Nausea07.01.07.001--
Non-Hodgkin's lymphoma01.17.01.001; 16.35.01.001--Not Available
Nystagmus17.02.02.006; 06.05.02.006--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Sensory loss17.02.07.007--Not Available
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Vomiting07.01.07.003--
Emotional distress19.04.02.008--Not Available
The 1th Page    1    Total 1 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene